These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6175406)

  • 1. Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer.
    Benz C; Tillis T; Tattelman E; Cadman E
    Cancer Res; 1982 May; 42(5):2081-6. PubMed ID: 6175406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of intermediate-dose methotrexate and high-dose 5-fluorouracil as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic adenocarcinoma of the colon.
    Tisman G; Wu SJ
    Cancer Treat Rep; 1980; 64(8-9):829-35. PubMed ID: 7448820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen and 5-fluorouracil in breast cancer: cytotoxic synergism in vitro.
    Benz C; Cadman E; Gwin J; Wu T; Amara J; Eisenfeld A; Dannies P
    Cancer Res; 1983 Nov; 43(11):5298-303. PubMed ID: 6616464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.
    Ribas A; Albanell J; Solé-Calvo LA; Gallardo E; Bellmunt J; Vera R; Vidal R; Carulla J; Baselga J
    Cancer; 1998 Mar; 82(5):878-85. PubMed ID: 9486577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of high-dose oral methotrexate sequenced at 24 hours with 5-FU: a clinical toxicity study.
    Benz C; Silverberg M; Cadman E
    Cancer Treat Rep; 1983 Mar; 67(3):297-9. PubMed ID: 6831477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8.
    Benz C; Cadman E
    Cancer Res; 1981 Mar; 41(3):994-9. PubMed ID: 7459888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study.
    Klaassen U; Wilke H; Müller C; Borquez D; Harstrick A; Seeber S
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-58-S17-60. PubMed ID: 9374095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells.
    Cadman E; Heimer R; Benz C
    J Biol Chem; 1981 Feb; 256(4):1695-704. PubMed ID: 6161926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
    Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
    Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S;
    Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice.
    Elliott WL; Howard CT; Dykes DJ; Leopold WR
    Cancer Res; 1989 Oct; 49(20):5586-90. PubMed ID: 2477146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.
    Sobrero AF; Aschele C; Guglielmi AP; Mori AM; Tixi LM; Bolli EA; Rosso R; Mammoliti S; Rollandi GA; Bertoglio S
    Clin Cancer Res; 1995 Sep; 1(9):955-60. PubMed ID: 9816066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy.
    Fryar EB; Das JR; Davis JH; Desoto JA; Laniyan I; Southerland WM; Bowen D
    Anticancer Res; 2006; 26(3A):1861-7. PubMed ID: 16827118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
    Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
    Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.